IL161851A0 - Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs - Google Patents

Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs

Info

Publication number
IL161851A0
IL161851A0 IL16185102A IL16185102A IL161851A0 IL 161851 A0 IL161851 A0 IL 161851A0 IL 16185102 A IL16185102 A IL 16185102A IL 16185102 A IL16185102 A IL 16185102A IL 161851 A0 IL161851 A0 IL 161851A0
Authority
IL
Israel
Prior art keywords
catsand
dogs
formulations
bacterial infections
treating bacterial
Prior art date
Application number
IL16185102A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL161851A0 publication Critical patent/IL161851A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL16185102A 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs IL161851A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US39893202P 2002-07-26 2002-07-26
PCT/IB2002/004743 WO2003045435A1 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs

Publications (1)

Publication Number Publication Date
IL161851A0 true IL161851A0 (en) 2005-11-20

Family

ID=26991236

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16185102A IL161851A0 (en) 2001-11-30 2002-11-13 Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs
IL161851A IL161851A (en) 2001-11-30 2004-05-06 Formulations comprising a cephalosporin compound and their use for treating bacterial infections in cats and dogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161851A IL161851A (en) 2001-11-30 2004-05-06 Formulations comprising a cephalosporin compound and their use for treating bacterial infections in cats and dogs

Country Status (28)

Country Link
US (1) US7378408B2 (no)
EP (1) EP1448234B1 (no)
JP (1) JP4689959B2 (no)
KR (1) KR100621291B1 (no)
CN (1) CN100502873C (no)
AR (1) AR037595A1 (no)
AT (1) ATE406916T1 (no)
AU (1) AU2002348986B2 (no)
BR (1) BRPI0214583B1 (no)
CA (1) CA2468708C (no)
CY (1) CY1108437T1 (no)
DE (1) DE60228749D1 (no)
DK (1) DK1448234T3 (no)
EA (1) EA008503B1 (no)
ES (1) ES2307800T3 (no)
HK (1) HK1071292A1 (no)
HR (1) HRP20040487A2 (no)
IL (2) IL161851A0 (no)
IS (1) IS7214A (no)
MA (1) MA27085A1 (no)
MX (1) MXPA04003724A (no)
NO (1) NO334818B1 (no)
NZ (1) NZ532208A (no)
PL (1) PL212683B1 (no)
PT (1) PT1448234E (no)
TN (1) TNSN04097A1 (no)
TW (1) TWI248363B (no)
WO (1) WO2003045435A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
DE602005002742T2 (de) * 2004-04-22 2008-01-24 Pfizer Products Inc., Groton Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
UA91205C2 (ru) * 2004-12-17 2010-07-12 Венус Ремедиз Лимитед Антибиотическая комбинация амикацина и цефепима для создания общего раствора для лечения инфекций
UA91208C2 (ru) * 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний
US20080318919A1 (en) * 2005-10-29 2008-12-25 Intervet International B.V. Cefquinome Compositions and Methods of Their Use
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
JP2011514902A (ja) * 2008-03-04 2011-05-12 エラン・ファルマ・インターナショナル・リミテッド 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8784385B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
KR102226197B1 (ko) * 2013-03-15 2021-03-11 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
PT3319596T (pt) * 2015-07-09 2024-01-17 Uniwell Laboratories Llc Composições farmacêuticas
RU2018112431A (ru) 2015-09-07 2019-10-09 Мотида Фармасьютикал Ко., Лтд. Лиофилизированный препарат альгиновой кислоты
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
EP3687504A1 (en) 2017-09-27 2020-08-05 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
GB2575261B (en) 2018-07-02 2022-03-09 Norbrook Lab Ltd Intermediates in the synthesis of C3-substituted cephalosporins
CN109393004A (zh) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 一种利用冻品自由水升华实现真空解冻的方法
KR20240105503A (ko) * 2021-11-26 2024-07-05 아스테라스 세이야쿠 가부시키가이샤 인도시아닌 화합물 함유 고형 의약 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5711909A (en) 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (ja) 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5138066A (en) 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
ZA89829B (en) 1988-02-05 1990-10-31 Lilly Co Eli Crystalline b-lactam solvate
CA2024587A1 (en) * 1989-09-05 1991-03-06 Bernard Ecanow Drug delivery compositions based on biological cells or components thereof and methods
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US6020329A (en) 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
US6001997A (en) 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2001199889A (ja) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd 縮合ピリダジン誘導体を含有してなる点鼻用剤
EP1246668B1 (en) 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
AU2394302A (en) * 2000-12-04 2002-06-18 Pfizer Prod Inc Coupling process and intermediates useful for preparing cephalosphorins

Also Published As

Publication number Publication date
EP1448234B1 (en) 2008-09-03
PL212683B1 (pl) 2012-11-30
JP4689959B2 (ja) 2011-06-01
TWI248363B (en) 2006-02-01
HK1071292A1 (en) 2005-07-15
MXPA04003724A (es) 2005-04-08
US20030186957A1 (en) 2003-10-02
ES2307800T3 (es) 2008-12-01
EP1448234A1 (en) 2004-08-25
CN100502873C (zh) 2009-06-24
PL370083A1 (en) 2005-05-16
CA2468708C (en) 2008-08-19
AR037595A1 (es) 2004-11-17
AU2002348986B2 (en) 2008-04-03
DK1448234T3 (da) 2008-11-03
BR0214583A (pt) 2004-11-03
EA008503B1 (ru) 2007-06-29
WO2003045435A1 (en) 2003-06-05
CN1604793A (zh) 2005-04-06
AU2002348986A1 (en) 2003-06-10
TNSN04097A1 (fr) 2006-06-01
BRPI0214583B1 (pt) 2015-11-17
ATE406916T1 (de) 2008-09-15
PT1448234E (pt) 2008-10-02
NZ532208A (en) 2007-01-26
JP2005511642A (ja) 2005-04-28
CA2468708A1 (en) 2003-06-05
IS7214A (is) 2004-04-07
HRP20040487A2 (en) 2004-10-31
KR20040058345A (ko) 2004-07-03
IL161851A (en) 2011-11-30
EA200400489A1 (ru) 2004-10-28
CY1108437T1 (el) 2014-04-09
DE60228749D1 (de) 2008-10-16
TW200300351A (en) 2003-06-01
KR100621291B1 (ko) 2006-09-13
MA27085A1 (fr) 2004-12-20
NO20042271L (no) 2004-07-22
NO334818B1 (no) 2014-06-02
US7378408B2 (en) 2008-05-27

Similar Documents

Publication Publication Date Title
IL161851A0 (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in catsand dogs
AU2001286878A1 (en) Oxazolidinones and their use as antibacterial agents
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
PT2311466E (pt) Compostos antimicrobianos e métodos para a sua utilização
AU2001272935A1 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
HK1082193A1 (en) Antibacterial agent and antibacterial composition
SI1427711T1 (sl) Oksazolidinonski in/ali izoksazolinski derivati kot antibakterijska sredstva
AU2002218365A1 (en) Heterocyclylalkyl piperidine derivatives and their use as antimicrobial agents
AU2002346388A1 (en) Absorbent component and use as pet litter
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2003292422A1 (en) Oxazolidinone derivatives and their use as antibacterial agents
AU2001275736A1 (en) Improvements in animal cages
AU2002358036A1 (en) Methods and compositions for use in pet breeding
EP1511753A4 (en) ANTIMICROBIAL MEDIUM AND ITS USE
HK1052643A1 (en) Use of pleuromutilin derivatives in the manufacture of a mediament for transdermal treatment of bacterial infections in humans and animals
PL361836A1 (en) Prevention of hoof infections in stockbreeding
AU2001251370A1 (en) Antimicrobial methods and materials
GB0018887D0 (en) Compound and their therapeutic use
AU2001267565A1 (en) Anthelminthic agents for the prevention of parasitic infections in humans and animals II
AU3002901A (en) Bacterial galactanases and use thereof
AU2002211637A1 (en) Probiotic compositions and methods against bacterial infection in livestock animals
AU2535600A (en) Bacterial galactanases and use thereof
NO20043008L (no) Fremgangsmate for behandling av bakterielle infeksjoner i hunder og katter
AU2003209241A1 (en) Antimicrobial thiadiazinone derivatives useful in treatment of bacterial infections
AU2001289612A1 (en) Anthelmintics for preventing parasitic infections in humans and animals